---
title: "VRDN: FDA approves Lumvoa for TED, offering rapid, durable relief and broad patient access"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291165211.md"
description: "Lumvoa received FDA approval as the first TED therapy with data for both active and chronic patients, offering rapid, durable symptom relief in a short 12-week regimen. Launch targets a $2B market with a focused commercial strategy, broad payer access expected in 6–9 months, and a robust patient support program.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-29T14:52:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291165211.md)
  - [en](https://longbridge.com/en/news/291165211.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291165211.md)
generator: "portal-rs"
---

# VRDN: FDA approves Lumvoa for TED, offering rapid, durable relief and broad patient access

Lumvoa received FDA approval as the first TED therapy with data for both active and chronic patients, offering rapid, durable symptom relief in a short 12-week regimen. Launch targets a $2B market with a focused commercial strategy, broad payer access expected in 6–9 months, and a robust patient support program.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)

## Related News & Research

- [12:25 ETRaymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)](https://longbridge.com/en/news/292931199.md)
- [Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease | VRDN Stock News](https://longbridge.com/en/news/291012432.md)
- [Xeris to host XP-8121 hypothyroidism program overview webinar](https://longbridge.com/en/news/297037117.md)
- [Thyroid tablets recalled nationwide over potential 'superpotency': FDA](https://longbridge.com/en/news/296939459.md)
- [Cytokinetics Investors Weigh Safety Data From Pivotal Trial](https://longbridge.com/en/news/297549493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**